World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 19 February 2015
Main ID:  NCT01687647
Date of registration: 31/08/2012
Prospective Registration: Yes
Primary sponsor: University Hospital, Caen
Public title: Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure AMORCE-CBP
Scientific title: Interest of Morphometric Analysis of Sputum Cytology for Lung Cancer Screening in Workers Highly Exposed to Asbestos - Exploratory Analysis of Biomarkers Predictive for Lung Cancer
Date of first enrolment: September 2012
Target sample size: 1000
Recruitment status: Enrolling by invitation
Study type:  Interventional
Study design:  Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Screening  
Phase:  Phase 3
Countries of recruitment
Name:     Lydia GUITTET, MD,PhD
Affiliation:  Caen University Hospital, INSERM
Key inclusion & exclusion criteria

Inclusion Criteria:

- High professional asbestos exposure

- Member of a former cohort recruited between 2000 and 2006 in Caen, Rouen and Le Havre
(inclusion criteria: 50-75 years at the time of initial recruitment, high
intermittent asbestos exposure >= 1 year, or high discontinuous asbestos exposure
>=10 years). All the living members of the cohort will be contacted: a maximum of
1000 subjects is expected, probably less.

- Informed consent signed

Exclusion Criteria:

- Personal history of lung cancer

- Refusal of the study protocol

- Uncontrolled asthma or lung failure

Age minimum: 56 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Lung Neoplasms
Other: low-dose CT-scan AND induced sputum sample AND blood test
Primary Outcome(s)
detection of lung cancer [Time Frame: within 3 months]
Risk of false positive [Time Frame: within 3 months]
Secondary Outcome(s)
Predictive Biomarkers [Time Frame: Annually during a maximum of 5 years]
Sensitivity for lung cancer detection compared with CT-scan [Time Frame: within 3 months]
Specificity for detection of lung cancer [Time Frame: within 3 months]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ministry of Health, France
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history